Quest Diagnostics Q3 2024 Adj. EPS $2.30 Beats $2.26 Estimate, Sales $2.488B Beat $2.423B Estimate
Portfolio Pulse from Benzinga Newsdesk
Quest Diagnostics reported its Q3 2024 financial results, with adjusted EPS of $2.30, surpassing the estimate of $2.26. The company's sales also exceeded expectations, reaching $2.488 billion compared to the estimated $2.423 billion.
October 22, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quest Diagnostics' Q3 2024 earnings report shows a positive performance, with both EPS and sales surpassing analyst estimates. This indicates strong operational efficiency and market demand.
The company's ability to exceed both EPS and sales estimates suggests strong financial health and operational success. This is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100